CBDL OTC
CBD Life Sciences Inc.
1W: +0.0%
1M: -50.0%
3M: -66.7%
YTD: -50.0%
1Y: -83.3%
3Y: -100.0%
5Y: -100.0%
$0.00
-0.00 (-50.00%)
Weekly Expected Move ±70.3%
$-0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$98K
-9.7% ▼
5Y CAGR: -15.3%
Gross Profit
$41K
+519.5% ▲
Operating Income
-$102K
+86.6% ▲
Net Income
-$49K
+93.5% ▲
EPS (Diluted)
$0.00
+100.0% ▲
EBITDA
-$102K
+85.5% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $59K | $160K | $167K | $109K | $98K |
| YoY Growth | -73.8% | +170.4% | +4.3% | -34.9% | -9.7% |
| Cost of Revenue | $208K | $441K | $198K | $119K | $57K |
| Gross Profit | -$148K | -$280K | -$31K | -$10K | $41K |
| Gross Margin | -250.2% | -174.9% | -18.3% | -9.1% | 42.2% |
| R&D Expenses | $0 | $0 | $0 | $0 | $0 |
| SG&A Expenses | $6M | $572K | $46K | $747K | $143K |
| Operating Expenses | $5M | $580K | $48K | $747K | $143K |
| Operating Income | -$5M | -$860K | -$79K | -$757K | -$102K |
| Operating Margin | -8654.2% | -536.6% | -47.0% | -695.4% | -103.4% |
| Interest Expense | $0 | $0 | $0 | $0 | $0 |
| Income Before Tax | -$5M | -$860K | -$79K | -$757K | -$49K |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$5M | -$860K | -$79K | -$757K | -$49K |
| Net Margin | -8654.2% | -536.6% | -47.0% | -695.4% | -49.8% |
| EPS (Diluted) | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $0.00 |
| EBITDA | -$5M | -$806K | -$23K | -$702K | -$102K |
| Shares Outstanding | 1.23B | 4.07B | 136M | 3.10B | 4.11B |